| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Accuracy of a dedicated 100 Hz vibration-controlled spleen stiffness measurement for the detection of esophageal varices in naïve patients with compensated advanced chronic liver disease: interim results from a multicentric cohort
|
Armandi, A.
|
|
|
56 |
S1 |
p. S66-S67
|
article
|
| 2 |
Acute-on-chronic liver failure in severe acute alcoholic hepatitis: impact on management, prognostication, and urgency of liver transplantation
|
Perricone, G.
|
|
|
56 |
S1 |
p. S39
|
article
|
| 3 |
Aetiology of hepatocellular carcinoma and response to immunotherapy: is the problem inherent in the classification of non-viral disease?
|
Tovoli, F.
|
|
|
56 |
S1 |
p. S92-S93
|
article
|
| 4 |
A.I.S.F. 2024: Abstracts Evaluation Procedure
|
|
|
|
56 |
S1 |
p. S99
|
article
|
| 5 |
Alcoholic aetiology and severity of liver disease is correlated with worse Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) in liver transplant candidates (LT) and correlates with post-transplant adherence
|
Zanatta, E.
|
|
|
56 |
S1 |
p. S46
|
article
|
| 6 |
A Markov model unveiling the impact of Resmetirom on the natural history of MASLD patients with baseline significant or severe liver fibrosis
|
Pennisi, G.
|
|
|
56 |
S1 |
p. S14
|
article
|
| 7 |
A modified Charlson Comorbidity Index to improve management of patients with hepatocellular carcinoma: a step towards precision medicine
|
Alimenti, E.
|
|
|
56 |
S1 |
p. S81
|
article
|
| 8 |
A multi-center comparative study of Atezolizumab plus Bevacivumab and Lenvatinib as primary systemic therapy for unresectable hepatocellular carcinoma (HCC): focus on thrombotic and hemorrhagic adverse events
|
Tizzani, M.
|
|
|
56 |
S1 |
p. S84
|
article
|
| 9 |
Analysis of HBV integration in mitochondrial DNA of HepAD38 cells by the high-throughput HBV integration sequencing and RNASeq approaches
|
Musolino, C.
|
|
|
56 |
S1 |
p. S1-S2
|
article
|
| 10 |
Application of Machine Learning Model-3P to Predict Portal Hypertension in Patient with Hepatocellular Carcinoma
|
Berardi, F.
|
|
|
56 |
S1 |
p. S87-S88
|
article
|
| 11 |
ASAP score may predict HCC recurrence after complete radiological response to locoregional treatments
|
Canova, L.
|
|
|
56 |
S1 |
p. S89
|
article
|
| 12 |
Assessment of sarcopenia and outcome with ultrasound-based measurements in patients with liver cirrhosis
|
Flagiello, V.
|
|
|
56 |
S1 |
p. S71-S72
|
article
|
| 13 |
Association between severity of liver and cardiovascular damage in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) according to cardiovascular risk categories
|
Currà, J.
|
|
|
56 |
S1 |
p. S52
|
article
|
| 14 |
Autoimmune hepatitis cholestatic variant syndromes recurrence following liver transplantation affects graft and patient survival in an international multicentre cohort
|
Ronca, V.
|
|
|
56 |
S1 |
p. S26-S27
|
article
|
| 15 |
Autoimmune hepatitis in Italy, changing epidemiology or increased awareness? Evidence from a 40-years referral-centre study
|
Ferronato, M.
|
|
|
56 |
S1 |
p. S22-S23
|
article
|
| 16 |
Bacterial and Fungal Infections in ACLF: prevalence and impact on patient morbidity and mortality
|
Iegri, C.
|
|
|
56 |
S1 |
p. S74-S75
|
article
|
| 17 |
Baseline predictors of virological and biochemical responses in HDV compensated cirrhotic patients treated with Bulevirtide monotherapy (HEP4Di study)
|
Degasperi, E.
|
|
|
56 |
S1 |
p. S32-S33
|
article
|
| 18 |
Biochemical response to obeticholic acid drives liver stiffness variation over time and the risk of liver-related events in patients with primary biliary cholangitis
|
De Vincentis, A.
|
|
|
56 |
S1 |
p. S21-S22
|
article
|
| 19 |
Bulevirtide monotherapy prevents liver decompensation and reduces mortality in patients with HDV-related cirrhosis: a case control study with propensity score weighted analysis
|
Degasperi, E.
|
|
|
56 |
S1 |
p. S31-S32
|
article
|
| 20 |
Bulevirtide progressively improves liver function in liver transplant candidates with advanced HDV cirrhosis and severe portal hypertension
|
Loglio, A.
|
|
|
56 |
S1 |
p. S34
|
article
|
| 21 |
Burden of Hepatitis D Virus infection in Italy: interim results from a prospective multicentre nationwide study
|
Caviglia, G.P.
|
|
|
56 |
S1 |
p. S16
|
article
|
| 22 |
Can AtezoBev be a safe and effective option for treating hepatocellular carcinoma in patients with Child-Pugh B cirrhosis? A retrospective multicenter real-world study
|
Stella, L.
|
|
|
56 |
S1 |
p. S78
|
article
|
| 23 |
Changes in mean arterial pressure are inadequate to guide treatment with terlipressin and albumin in patients with hepatorenal syndrome - acute kidney injury
|
Calvino, V.
|
|
|
56 |
S1 |
p. S64
|
article
|
| 24 |
Characteristics and management of hepatocellular carcinoma (HCC) in Sicily: first results of the HCC Sicily Multidisciplinary Network
|
Celsa, C.
|
|
|
56 |
S1 |
p. S83-S84
|
article
|
| 25 |
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
|
Celsa, C.
|
|
|
56 |
S1 |
p. S76-S78
|
article
|
| 26 |
Characterization by polygenic risk score of a dysmetabolic population of Southern Italy
|
Motta, B.M.
|
|
|
56 |
S1 |
p. S60
|
article
|
| 27 |
Cholestasis impacts on performance of non invasive tests for ruling out high-risk esophageal varices in patients with primary biliary cholangitis and compensated advanced chronic liver disease
|
Calvaruso, V.
|
|
|
56 |
S1 |
p. S28
|
article
|
| 28 |
Chrononutrition as a dietary strategy to reduce hepatic steatotis in patients with metabolic dysfunction-associated steatotic liver disease
|
Castelnuovo, G.
|
|
|
56 |
S1 |
p. S49
|
article
|
| 29 |
Circulating mitochondrial bioenergetic profile reflects the hepatic one and represents a non-invasive biomarker of disease severity in MASLD genetically predisposed individuals
|
Paolini, E.
|
|
|
56 |
S1 |
p. S11-S12
|
article
|
| 30 |
CiThroModel improves the prediction of venous thromboembolism in hospitalized patients with cirrhosis
|
Zanetto, A
|
|
|
56 |
S1 |
p. S6
|
article
|
| 31 |
Clinical impact of contrast-enhanced ultrasound on indeterminate or non-characterizable liver nodules on CT/MRI: sub-analysis from a prospective multicenter trial
|
Piscaglia, F.
|
|
|
56 |
S1 |
p. S2-S3
|
article
|
| 32 |
Clinical outcomes of metabolic liver disease versus non-alcoholic fatty liver disease: a meta-analysis of observational studies
|
Pennisi, G.
|
|
|
56 |
S1 |
p. S50
|
article
|
| 33 |
Clinical predictors of liver and diabetes outcomes in cirrhotic patients with type 2 diabetes
|
Grisanti, C.
|
|
|
56 |
S1 |
p. S72
|
article
|
| 34 |
Comparative analysis of subclassification models in patients with intermediate stage hepatocellular carcinoma (BCLC B) receiving systemic therapy
|
Ielasi, L.
|
|
|
56 |
S1 |
p. S85
|
article
|
| 35 |
Competitive Risk Analysis of Spleen Stiffness Measurement with a Spleen-Dedicated Module (SSM@100Hz) for Predicting de-novo HCC Occurrence in cACLD Patients: A Prospective 5-Year Follow-up Study
|
Ravaioli, F.
|
|
|
56 |
S1 |
p. S80-S81
|
article
|
| 36 |
Concomitant use of proton pump inhibitors and Sofosbuvir/Velpatasvir: evidence from randomized clinical trials and real-world data
|
Esteban, R.
|
|
|
56 |
S1 |
p. S37-S38
|
article
|
| 37 |
Cost analysis of Wilson's disease in Italy: a retrospective cohort study
|
Mennini, F.S.
|
|
|
56 |
S1 |
p. S47
|
article
|
| 38 |
CXCL3 is a target of miR-30e-3p and predicts tumor escape in sorafenib-treated HCC patients
|
Vianello, C.
|
|
|
56 |
S1 |
p. S94
|
article
|
| 39 |
Decoding human Intrahepatic Cholangiocarcinoma Metabolism: Unveiling the Impact of SLC2A3 on Aggressiveness and Prognosis
|
Polidoro, M.A.
|
|
|
56 |
S1 |
p. S6-S7
|
article
|
| 40 |
Detection of coronary artery disease in liver transplant recipients: does stress echocardiography still have a role?
|
Saracco, M.
|
|
|
56 |
S1 |
p. S42
|
article
|
| 41 |
Do ACE inhibitors have a role in preventing drug-related proteinuria in advanced HCC patients?
|
Stefanini, B.
|
|
|
56 |
S1 |
p. S92
|
article
|
| 42 |
Does HLA-G play a role in PBC?
|
Miglianti, M.
|
|
|
56 |
S1 |
p. S26
|
article
|
| 43 |
“Early” vs “standard” liver transplantation in patients with severe alcoholic hepatitis
|
Viganò, R.
|
|
|
56 |
S1 |
p. S41
|
article
|
| 44 |
Efficacy and safety of atezolizumab/bevacizumab for hepatocellular carcinoma in a real-life prospective cohort: data from a multicenter collaborative study
|
Tovoli, F.
|
|
|
56 |
S1 |
p. S85-S86
|
article
|
| 45 |
Efficacy and safety of lusutrombopag in a real-world Italian series of cirrhotic patients with severe thrombocytopenia undergoing invasive procedures: the Reality study
|
Gallo, P.
|
|
|
56 |
S1 |
p. S69-S70
|
article
|
| 46 |
Eliminating HCV infection from prisons in sicily: the SINTESI project
|
Di Marco, L.
|
|
|
56 |
S1 |
p. S15
|
article
|
| 47 |
Emerging metabolic and alcoholic etiologies in liver cirrhosis are related to high rate of recurrence after first episode of decompensation
|
Masetti, C.
|
|
|
56 |
S1 |
p. S76
|
article
|
| 48 |
Emerging role of Spleen Stiffness Measurement in prediction of clinically significant portal hypertension: a single center experience
|
Capasso, M.
|
|
|
56 |
S1 |
p. S76
|
article
|
| 49 |
End-procedural complete haemodynamic response may not be essential for the clinical success of TIPS in patients with cirrhosis
|
Roccarina, D.
|
|
|
56 |
S1 |
p. S5-S6
|
article
|
| 50 |
Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis
|
Nardelli, S.
|
|
|
56 |
S1 |
p. S67
|
article
|
| 51 |
Evaluation of ChatGPT as a counselling tool for Italian-speaking MASLD patients: assessment of accuracy, completeness and comprehensiveness
|
Pugliese, N.
|
|
|
56 |
S1 |
p. S54
|
article
|
| 52 |
Exploring occupational toxicant exposures in patients with metabolic dysfunction-associated steatotic liver disease: a prospective pilot study
|
Tovoli, F.
|
|
|
56 |
S1 |
p. S53
|
article
|
| 53 |
Exploring the role of aMAP and Toronto score: beyond diagnosis to prognosis
|
Cespiati, A.
|
|
|
56 |
S1 |
p. S93
|
article
|
| 54 |
Expression of deiodinases-3 in HCC as predictor of poor tumor differentiation
|
Cossiga, V.
|
|
|
56 |
S1 |
p. S97-S98
|
article
|
| 55 |
Ex situ liver resection for intrahepatic cholangiocarcinoma: survival analysis and comparison to systemic chemotherapy
|
Nieddu, E.
|
|
|
56 |
S1 |
p. S42
|
article
|
| 56 |
External Validation of the ExPeCT TIPS Prediction Model in a North American Cohort
|
Wang, R.X.
|
|
|
56 |
S1 |
p. S63-S64
|
article
|
| 57 |
Fatigue is not influenced by chronotype and is reported to be mainly muscular in patients with primary biliary cholangitis
|
Lynch, E.N.
|
|
|
56 |
S1 |
p. S29
|
article
|
| 58 |
First and further liver decompensation in patients with metabolic-dysfunction associated steatotic liver disease: what clinical impact?
|
Pennisi, G.
|
|
|
56 |
S1 |
p. S56
|
article
|
| 59 |
Full Title Page /Editorial Board
|
|
|
|
56 |
S1 |
p. i-ii
|
article
|
| 60 |
Gender-related differences of hepatic lipid metabolism and mitochondrial function in genetically epileptic rats: effect of early lipopolysaccharide exposure
|
Melini, S.
|
|
|
56 |
S1 |
p. S59
|
article
|
| 61 |
Growth differentiation factor 15 performance as a novel non-invasive circulating biomarker of liver damage in paediatric non-alcoholic fatty liver disease
|
Mosca, A.
|
|
|
56 |
S1 |
p. S3
|
article
|
| 62 |
Hepatic sarcoidosis:an Italian multicenter study
|
Della Corte, C.
|
|
|
56 |
S1 |
p. S24-S25
|
article
|
| 63 |
Hepatitis B surface antigen positive donors for liver recipients with hepatocellular carcinoma: a single centre experience
|
Magro, B.
|
|
|
56 |
S1 |
p. S33-S34
|
article
|
| 64 |
Hepatocellular carcinoma incidence and risk stratification in patients with metabolic dysfunction-associated steatotic liver disease on long-term follow-up
|
Caviglia, G.P.
|
|
|
56 |
S1 |
p. S12
|
article
|
| 65 |
Hepatofugal portal flow is highly predictive of acute-on-chronic liver failure: a new hemodynamic patho-physiological hypothesis
|
De Marco, L.
|
|
|
56 |
S1 |
p. S40
|
article
|
| 66 |
Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma
|
Manfredi, G.F.
|
|
|
56 |
S1 |
p. S8-S9
|
article
|
| 67 |
Identification of key predictors of significant weight loss in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a multicentre study
|
Arcari, I.
|
|
|
56 |
S1 |
p. S52
|
article
|
| 68 |
Immunosuppressive contribution of tumor-infiltrating B cell subsets in human intrahepatic cholangiocarcinoma and their role in immunotherapy response
|
Milardi, G.
|
|
|
56 |
S1 |
p. S94-S95
|
article
|
| 69 |
Impact of acute on chronic liver failure (aclf) superimposed to alcoholic cirrhosis: a single centre experience
|
Ideo, F.
|
|
|
56 |
S1 |
p. S73-S74
|
article
|
| 70 |
Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease
|
Marchetti, A.
|
|
|
56 |
S1 |
p. S82-S83
|
article
|
| 71 |
Impact of first microbial infection on outcomes in natural history and trajectories in cirrhosis
|
Bucci, M.
|
|
|
56 |
S1 |
p. S44
|
article
|
| 72 |
Impact of maralixibat on cholestatic pruritus in young adults aged 16 years and older with Alagille syndrome
|
Hirschfield, G.
|
|
|
56 |
S1 |
p. S27-S28
|
article
|
| 73 |
Impact of pre-transplant cardiac risk factor burden on post-transplant events in liver transplant recipients
|
Lasco, R.
|
|
|
56 |
S1 |
p. S43
|
article
|
| 74 |
Improved handling of BCLC 2022 update in the management of hepatocellular carcinoma in clinical practice
|
Alimenti, E.
|
|
|
56 |
S1 |
p. S81-S82
|
article
|
| 75 |
Improvement of insulin resistance indicators in subjects with metabolic syndrome under treatment with Gliflozins: possible role in the control of the natural history of MASLD
|
Citarrella, R.
|
|
|
56 |
S1 |
p. S51
|
article
|
| 76 |
Improvement of non-invasive fibrosis tests in HDV cirrhotic patients with clinically significant portal hypertension responding to Bulevirtide monotherapy
|
Degasperi, E.
|
|
|
56 |
S1 |
p. S34
|
article
|
| 77 |
Improving Predictive Accuracy in Primary Biliary Cholangitis: A New Genetic Risk Score
|
Gerussi, A.
|
|
|
56 |
S1 |
p. S1
|
article
|
| 78 |
Induced regulatory T cells via cyclin-dependent kinase inhibition from patients with primary biliary cholangitis are suppressive and stable in an IFN enriched environment and are epigenetically different from natural regulatory T cells
|
Ronca, V.
|
|
|
56 |
S1 |
p. S19-S20
|
article
|
| 79 |
Intrahepatic cholangiocarcinoma-derived organoids for disease modelling and drug screening
|
De Siervi, S.
|
|
|
56 |
S1 |
p. S13
|
article
|
| 80 |
Involvement of the potassium channel ERG1 in cholangiocarcinoma
|
Iorio, J.
|
|
|
56 |
S1 |
p. S86
|
article
|
| 81 |
Kinetics of the three HBsAg forms along with HDV-RNA predict virological and biochemical responses in chronic hepatitis delta patients treated with bulevirtide for 48 weeks
|
D'Anna, S.
|
|
|
56 |
S1 |
p. S32
|
article
|
| 82 |
Lessons from HCV screening 1969-1989: moving to reflex HCV testing and multiparametric US of the liver for the goal of microelimination
|
Costa, E. Garlatti
|
|
|
56 |
S1 |
p. S35
|
article
|
| 83 |
Liposomal doxorubicin targeted with the Fab’ of atezolizumab exerts an immunomodulatory effect in in vitro models of hepatocellular carcinoma
|
Zanotto, I.
|
|
|
56 |
S1 |
p. S97
|
article
|
| 84 |
Liver Frailty Index predicts poor outcomes in patients hospitalized for acute decompensation of cirrhosis
|
Gagliardi, R.
|
|
|
56 |
S1 |
p. S70
|
article
|
| 85 |
Liver-related outcomes in patients with HCV compensated liver cirrhosis after SVR: results from 5-years of follow-up
|
Morisco, F.
|
|
|
56 |
S1 |
p. S35
|
article
|
| 86 |
Liver steatosis assessed by CAP in patients with primary biliary cholangitis
|
Bueti, F.
|
|
|
56 |
S1 |
p. S29-S30
|
article
|
| 87 |
Liver Transplant in ACLF and ALD: an effective option with limited access? Preliminary results of a single center experience
|
Ideo, F.
|
|
|
56 |
S1 |
p. S73
|
article
|
| 88 |
Longer transplant-free and liver-related event-free survival in obeticholic acid-treated patients with primary biliary cholangitis compared to external controls from two large real-world cohorts
|
Terracciani, F.
|
|
|
56 |
S1 |
p. S3-S5
|
article
|
| 89 |
Long-term albumin administration improves survival in outpatients with decompensated cirrhosis and diabetes: post-hoc analysis of the ANSWER Trial
|
Zaccherini, G.
|
|
|
56 |
S1 |
p. S65-S66
|
article
|
| 90 |
Long-term therapy with intravenous human albumin increase survival in patients with decompensated cirrhosis and refractory ascites
|
Lombardo, A.
|
|
|
56 |
S1 |
p. S69
|
article
|
| 91 |
MAIT cells play a role in liver tissue repair via growth factor secretion
|
Sayaf, K.
|
|
|
56 |
S1 |
p. S61
|
article
|
| 92 |
Management of portal hypertension in patients receiving atezolizumab-bevacizumab for hepatocellular carcinoma
|
Tovoli, F.
|
|
|
56 |
S1 |
p. S87
|
article
|
| 93 |
Material deprivation is associated with liver stiffness measurement and liver-related events in people with HIV
|
Cinque, F.
|
|
|
56 |
S1 |
p. S75-S76
|
article
|
| 94 |
Mild overt hepatic encephalopathy (HE) - more than meets the eye
|
Erminelli, D.
|
|
|
56 |
S1 |
p. S70
|
article
|
| 95 |
MiR-22 regulates HIF-1A pathway and tumor progression and represents a possible biomarker of sorafenib response in hepatocellular carcinoma
|
Galvani, G.
|
|
|
56 |
S1 |
p. S96-S97
|
article
|
| 96 |
Modeling cancer cells and tumor vasculature dynamics by serum biomarkers in HCC patients with different response to TKIs, TACE and TARE suggests a synergistic effect of systemic and endovascular treatments
|
Damone, F.
|
|
|
56 |
S1 |
p. S84-S85
|
article
|
| 97 |
New steps forward in learning about the use of DGAT1 and DGAT2 inhibitors for MASLD management: limits and benefits for their single or combined application
|
Longo, M.
|
|
|
56 |
S1 |
p. S59
|
article
|
| 98 |
Non-invasive assessment of hepatic steatosis by ultrasound-derived fat fraction (UDFF) in individuals at high-risk for metabolic dysfunction-associated steatotic liver disease
|
Tavaglione, F.
|
|
|
56 |
S1 |
p. S51
|
article
|
| 99 |
Non-psychedelic doses of psilocybin as a novel therapeutic approach for MASLD
|
De Martin, S.
|
|
|
56 |
S1 |
p. S60
|
article
|
| 100 |
Non-selective beta-blockers lower the risk of first decompensation in patients with cirrhosis and enduring clinically significant portal hypertension after etiological treatment
|
Turco, L.
|
|
|
56 |
S1 |
p. S2
|
article
|
| 101 |
Novel insights into the effect of SGLT-2 inhibitor empagliflozin on hepatic damage in diabetic obese Zucker rats
|
Pirozzi, C.
|
|
|
56 |
S1 |
p. S13
|
article
|
| 102 |
Off-label use of nivolumab beyond first-line in advanced hepatocellular carcinoma: a report of two international experiences
|
Frigo, F.
|
|
|
56 |
S1 |
p. S88
|
article
|
| 103 |
Optimizing AI Performance for Autoimmune Hepatitis Guidelines: A Case Study on Enhanced GPT Model Accuracy
|
Giuffrè, M.
|
|
|
56 |
S1 |
p. S28
|
article
|
| 104 |
Oxidative stress-induced fibrinogen modifications in liver transplant recipients: unraveling a novel potential mechanism for cardiovascular risk
|
Gitto, S.
|
|
|
56 |
S1 |
p. S40
|
article
|
| 105 |
Parenchymal renal cell carcinoma is associated with occult hepatitis B virus infection
|
Lombardo, D.
|
|
|
56 |
S1 |
p. S30-S31
|
article
|
| 106 |
Pathways sustaining HDV activity act independently from the size of HBV resevoir and are fueled by an abundant expression of HBsAg from integrated HBV-DNA
|
Salpini, R.
|
|
|
56 |
S1 |
p. S30
|
article
|
| 107 |
Patient voice on adherence and satisfaction following switch in therapy to trientine tetrahydrochloride for Wilson disease; the ASTRA study
|
Zuin, M.
|
|
|
56 |
S1 |
p. S45
|
article
|
| 108 |
Performance evaluation of hepatic venous pressure gradient (HVPG) score as predictor tool of liver-related events in patients with advanced chronic liver disease
|
Capasso, M.
|
|
|
56 |
S1 |
p. S75
|
article
|
| 109 |
Perfusate cytokines concentrations during liver grafts ex-situ normothermic perfusion (DCDNet Study)
|
Vacca, P.G.
|
|
|
56 |
S1 |
p. S42-S43
|
article
|
| 110 |
Pilot, open, randomized, multicenter trial for the comparison of hypothermic versus normothermic ex-situ liver preservation in DCD liver transplantation with extended ischemia time (DCDNet trial)
|
Bronzoni, J.
|
|
|
56 |
S1 |
p. S38-S39
|
article
|
| 111 |
1-Piperidine propionic acid is effective in reducing HCC development and fatty acid accumulation in experimental liver carcinogenesis
|
Guerra, P.
|
|
|
56 |
S1 |
p. S15
|
article
|
| 112 |
Placement of a trans-jugular intrahepatic portosystemic shunt (TIPS) modifies the expression of soluble mediators by circulating monocytes
|
Pastore, M.
|
|
|
56 |
S1 |
p. S71
|
article
|
| 113 |
PNPLA3 p.I148M variant affects lipid droplets number and size in patient-derived liver organoids
|
Casirati, E.
|
|
|
56 |
S1 |
p. S57
|
article
|
| 114 |
Predictors of clinical trajectories in patients surviving an acute decompensation of cirrhosis
|
Gambino, C.
|
|
|
56 |
S1 |
p. S67-S68
|
article
|
| 115 |
Preliminary evidence of the anti-steatotic effect of Abelmoschus esculentus extracts in in vitro models of MASLD
|
Gabbia, D.
|
|
|
56 |
S1 |
p. S46
|
article
|
| 116 |
Preoperative aortic regurgitation and early graft survival in liver transplant recipients
|
Biolato, M.
|
|
|
56 |
S1 |
p. S41
|
article
|
| 117 |
Prevalence and Characterization of Resistance Profiles of “Unusual” HCV Subtypes in Italy within the Italian Resistance Network Vironet C
|
Khalili, O. El
|
|
|
56 |
S1 |
p. S35-S36
|
article
|
| 118 |
Prevalence and clinical outcomes of different forms of renal dysfunction in patients hospitalized for decompensated cirrhosis: focus on acute kidney disease. A prospective observational study
|
Frigo, F.
|
|
|
56 |
S1 |
p. S61-S62
|
article
|
| 119 |
Prevalence of HCV infection in a nursing home: the unknown submerged population
|
Di Pasquale, G.
|
|
|
56 |
S1 |
p. S38
|
article
|
| 120 |
Prognostic role of ELF test compared to liver biopsy in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
|
Liguori, A.
|
|
|
56 |
S1 |
p. S12
|
article
|
| 121 |
Prospective 5-Year Follow-up Study of Spleen Stiffness Measurement with a Spleen-Dedicated Module (SSM@100Hz) for Predicting Hepatic Decompensation in cACLD: Competitive Risk Analysis
|
Colecchia, L.
|
|
|
56 |
S1 |
p. S62-S63
|
article
|
| 122 |
Psychopathology and coping strategies in MASLD-related compensated advanced chronic liver disease
|
Maggio, E.
|
|
|
56 |
S1 |
p. S53
|
article
|
| 123 |
Quantification of plasma HDV RNA in untreated and Bulevirtide-treated patients with CHD: a comparison between Robogene 2.0, Eurobioplex and Altostar
|
Anolli, M.P.
|
|
|
56 |
S1 |
p. S33
|
article
|
| 124 |
Radiomics-based prognostication in primary sclerosing cholangitis: a proof-of-concept study
|
Cristoferi, L.
|
|
|
56 |
S1 |
p. S11
|
article
|
| 125 |
Real-life assessment of long-term adverse events related to immunosuppression after liver transplantation: data from a cohort of patients followed-up in a non-transplant centre
|
Lynch, E.N.
|
|
|
56 |
S1 |
p. S43-S44
|
article
|
| 126 |
Real-life experience of long-term albumin treatment for the management of ascites in patients with decompensated cirrhosis accross Italy
|
Pompili, E.
|
|
|
56 |
S1 |
p. S20
|
article
|
| 127 |
Relationship of non-invasive measures with histological response in patients with nonalcoholic steatohepatitis and fibrosis: 52-week data from the Phase 3 MAESTRO-NASH trial
|
Mangia, A.
|
|
|
56 |
S1 |
p. S14
|
article
|
| 128 |
Repeated measurements and data integration to monitor and study MASLD patients experiencing weight loss
|
Torre, P.
|
|
|
56 |
S1 |
p. S55
|
article
|
| 129 |
RESIST-NASH: a regional network for identification and referral of masld patients at risk for liver fibrosis
|
Pennisi, G.
|
|
|
56 |
S1 |
p. S48-S49
|
article
|
| 130 |
Response to a 6-month personalized dietary intervention in patients with metabolic dysfunction-associated steatotic liver disease
|
Perez-Diaz-del-Campo, N.
|
|
|
56 |
S1 |
p. S55
|
article
|
| 131 |
Role of ganglioside GD2 in the stem-like compartment of intrahepatic cholangiocarcinoma
|
Mannini, A.
|
|
|
56 |
S1 |
p. S95-S96
|
article
|
| 132 |
Role of infections and therapies in the development of the different stages of hepatic decompensation
|
Vicardi, M.
|
|
|
56 |
S1 |
p. S64-S65
|
article
|
| 133 |
Role of P-shear wave hepatic elastography in prediction of high-risk varices in patients affected by compensated advanced chronic liver disease
|
Reggidori, N.
|
|
|
56 |
S1 |
p. S74
|
article
|
| 134 |
Role of rare and common variants in the diagnosis of adults with cryptogenic liver and lipid disorders
|
Ronzoni, L.
|
|
|
56 |
S1 |
p. S10
|
article
|
| 135 |
RUVBL1 correlates with chaperones expression in HCC and its activity is required for HSF1-mediated stress response
|
Mello, T.
|
|
|
56 |
S1 |
p. S97
|
article
|
| 136 |
Safety and Effectiveness of anticoagulation in patients with cirrhosis listed for liver transplantation: a single center observational study
|
Caccia, R.
|
|
|
56 |
S1 |
p. S68-S69
|
article
|
| 137 |
Safety and efficacy of direct oral anticoagulants in cirrhotic and non-cirrhotic patients with splanchnic vein thrombosis: preliminary results from sapient study
|
Giuli, L.
|
|
|
56 |
S1 |
p. S72-S73
|
article
|
| 138 |
Safety of direct-acting antivirals for Hepatitis C infection and direct oral anticoagulants co-administration: an Italian multicentric study
|
Rosato, V.
|
|
|
56 |
S1 |
p. S37
|
article
|
| 139 |
Semaglutide for type 2 diabetes control in metabolic dysfunction-associated steatotic liver disease (MASLD): a two-way effect?
|
Petralli, G.
|
|
|
56 |
S1 |
p. S50
|
article
|
| 140 |
Serum ammonia predicts mortality in patients with hepatocellular carcinoma
|
Guerra, P.
|
|
|
56 |
S1 |
p. S91-S92
|
article
|
| 141 |
Significant decrease of hepatic steatosis is associated with decreased PAI-I levels in overweight/obese subjects with Metabolic-dysfunction Associated Steatotic Liver Disease
|
Rosso, C.
|
|
|
56 |
S1 |
p. S54-S55
|
article
|
| 142 |
Sorafenib as a second-line treatment after failure of atezolizumab-bevacizumab
|
Tovoli, F.
|
|
|
56 |
S1 |
p. S79
|
article
|
| 143 |
Spleen stiffness measurement improves non-invasive prediction of clinically significant portal hypertension in primary biliary cholangitis
|
Manfredi, G.F.
|
|
|
56 |
S1 |
p. S23-S24
|
article
|
| 144 |
Steatotic liver in renal transplant recipients does not correlate with CVD, a retrospective cohort study
|
Secondulfo, C.
|
|
|
56 |
S1 |
p. S56-S57
|
article
|
| 145 |
Stereotactic body radiation therapy (SBRT) for HCC treatment: a single institution experience
|
Mazzarelli, C.
|
|
|
56 |
S1 |
p. S93-S94
|
article
|
| 146 |
Systolic and diastolic dysfunction in advanced liver disease: does cirrhotic cardiomyopathy really exist?
|
Bevilacqua, M.
|
|
|
56 |
S1 |
p. S45-S46
|
article
|
| 147 |
Targeting Hedgehog signaling pathway by a natural compound: a promising approach for anti-cancer therapeutic development in Intrahepatic Cholangiocarcinoma
|
Paradiso, S.
|
|
|
56 |
S1 |
p. S23
|
article
|
| 148 |
Targeting RuvBL1 reduces mTOR-driven NASH-HCC progression in conditional PTEN-KO mice
|
Guida, A.
|
|
|
56 |
S1 |
p. S96
|
article
|
| 149 |
Telomere length exhibits a strong association with non-alcoholic fatty liver disease progression in children
|
Braghini, M.R.
|
|
|
56 |
S1 |
p. S57
|
article
|
| 150 |
The effect of metabolic dysfunction-associated steatotic liver disease on liver fibrosis progression and regression in virus-related liver disease: a multicenter longitudinal study
|
Cinque, F.
|
|
|
56 |
S1 |
p. S47-S48
|
article
|
| 151 |
The equitable benefit approach (EBA): a single ethical framework to guide the assessment of medical and psychosocial factors in liver transplant candidacy
|
Craxì, L.
|
|
|
56 |
S1 |
p. S39
|
article
|
| 152 |
The glucokinase regulator gene (GCKR) rs780094 C>T single nucleotide polymorphism affect diet response in overweight/obese subjects with metabolic-dysfunction associated steatotic liver disease
|
Dileo, E.
|
|
|
56 |
S1 |
p. S49-S50
|
article
|
| 153 |
The impact of etiology on patterns of progression of advanced HCC
|
Stefanini, B.
|
|
|
56 |
S1 |
p. S17
|
article
|
| 154 |
The impact of metabolic risk factors on gender differences in HCC development and treatment allocation
|
Smith, D.
|
|
|
56 |
S1 |
p. S91
|
article
|
| 155 |
The IMPROVEMENT project: first report of the global liver transplant activity
|
Avolio, A.W.
|
|
|
56 |
S1 |
p. S17-S18
|
article
|
| 156 |
The levels of AFP, PIVKA and GPC-3 serum biomarkers at diagnosis correlate with HCC clinical-pathological features and with overall survival
|
Damone, F.
|
|
|
56 |
S1 |
p. S90
|
article
|
| 157 |
The OSM/OSMRβ signalling axis in the development of MASLD-related hepatocellular carcinoma
|
Nurcis, J.
|
|
|
56 |
S1 |
p. S95
|
article
|
| 158 |
The presence of sarcopenia at baseline seems to affect the fibrosis amelioration in patients with metabolic dysfunction associated steatotic liver disease
|
Santomenna, F.
|
|
|
56 |
S1 |
p. S47
|
article
|
| 159 |
The role of 2D-Shearwave elastography in non invasive portal hypertension diagnosis
|
Bronte, F.
|
|
|
56 |
S1 |
p. S66
|
article
|
| 160 |
The synergic effect of metformin with atezolizumab/ bevacizumab in masld hcc patients: a retrospective study from arte multicentric Italian dataset
|
Dalbeni, A.
|
|
|
56 |
S1 |
p. S89-S90
|
article
|
| 161 |
Tiny but powerful: platelets behaviour in metabolic dysfunction-associated steatotic liver disease and its evolution to liver cirrhosis
|
Zoncapè, M.
|
|
|
56 |
S1 |
p. S58
|
article
|
| 162 |
TKIs treatment for HCC before Liver transplantation: an ELITA/ELTR collaborative study
|
Mazzarelli, C.
|
|
|
56 |
S1 |
p. S86-S87
|
article
|
| 163 |
Transjugular intrahepatic portosystemic shunt after liver transplantation: is patient selection the key to success?
|
Leonardi, F.
|
|
|
56 |
S1 |
p. S18-S19
|
article
|
| 164 |
Transjugular intrahepatic portosystemic shunt (TIPS) in patients with vascular liver disorders: a comparative study
|
Becchetti, C.
|
|
|
56 |
S1 |
p. S68
|
article
|
| 165 |
Treatment of hepatocellular carcinoma according to multiparametric therapeutic hierarchy approach: a prospective multicenter validation study
|
Canova, L.
|
|
|
56 |
S1 |
p. S79-S80
|
article
|
| 166 |
Underdilated neoadjuvant-TIPS in patients with cirrhosis and portal hypertension candidates to operative interventions
|
Saltini, D.
|
|
|
56 |
S1 |
p. S64
|
article
|
| 167 |
Underdilation strategy for TIPS placement reduces incidence of overt hepatic encephalopathy without affecting clinical efficacy and survival: results of a multicenter prospective Italian study
|
Saltini, D.
|
|
|
56 |
S1 |
p. S10-S11
|
article
|
| 168 |
Unravelling the role of mitochondrial dysfunction in the switching towards progressive MASLD by exploiting an AMLN diet-fed mouse model
|
Paolini, E.
|
|
|
56 |
S1 |
p. S58
|
article
|
| 169 |
Validating and expanding Baveno VII criteria of recompensation in patients with decompensated cirrhosis
|
Tonon, M.
|
|
|
56 |
S1 |
p. S9-S10
|
article
|
| 170 |
Virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy for 96 weeks: a retrospective multicenter european study (SAVE-D)
|
Anolli, M.P.
|
|
|
56 |
S1 |
p. S7-S8
|
article
|
| 171 |
Whole blood thrombin generation improves the understanding of cirrhotic coagulopathy and predicts clinical outcomes in patients with cirrhosis: a prospective cohort study
|
Zanetto, A.
|
|
|
56 |
S1 |
p. S62
|
article
|
| 172 |
Yttrium-90 Radioembolization in hepatocellular treatment beyond the BCLC guidelines: a single center experience
|
Costantino, D.
|
|
|
56 |
S1 |
p. S90-S91
|
article
|
Journal description